Objective-To use protein kinase C (PKC) ␦knockout mice to investigate the role of PKC␦ in lesion development and to understand the underlying mechanism of the vascular disease. Methods and Results-PKC␦ functions as a signal transducer mediating several essential functions of cell proliferation and apoptosis. However, the effect of PKC␦ on neointimal formation in wire-injured vessels is unknown. Three weeks after wire injury of femoral arteries, neointimal lesions were significantly increased in PKC␦ Ϫ/Ϫ mice compared with PKC␦ ϩ/ϩ animals. Immunohistochemical staining revealed that total numbers of smooth muscle cells and macrophages in the lesions of PKC␦ Ϫ/Ϫ mice were markedly elevated without changing the ratio of these 2 cell types. To further elucidate the mechanisms of PKC␦-mediated increase in the lesion, an in vivo endothelial migration model was established to evaluate endothelial wound healing after wire injury. Data showed that reendothelialization of the injured vessel was markedly delayed in PKC␦ Ϫ/Ϫ mice; this coincided with more severe intimal hyperplasia. Migration of endothelial cells cultivated from cardiac tissue was markedly reduced in the absence of PKC␦, whereas no difference in proliferation or apoptosis was detected. Inhibition of PKC␦ activity or protein expression by small hairpin RNA (shRNA) in cultured endothelial cells confirmed the defective migratory phenotype. Interestingly, vasohibin-1, an antiangiogenesis protein, was elevated in endothelial cells derived from PKC␦ Ϫ/Ϫ mice, which was mainly because of delayed protein degradation mediated by PKC␦. Downregulation of vasohibin-1 restored the migration rate of PKC␦ Ϫ/Ϫ endothelial cells to a similar level as PKC␦ ϩ/ϩ cells. Conclusion-PKC␦ deficiency enhances neointimal formation, which is associated with delayed reendothelialization and involves increased cellular vasohibin-1 accumulation. (Arterioscler Thromb Vasc Biol. 2010;30:2467-2474.)
A rterial reconstruction procedures, such as balloon angioplasty, stenting, and vascular bypass surgery, are widely applied to patients with ischemic heart diseases. However, restenosis after clinic interventions significantly limits the application of such procedures and hampers the recovery rate of the patients. 1 Although vascular restenosis appears to be a major determinant of luminal stenosis after balloon angioplasty, neointimal formation can contribute to luminal narrowing. 2 One hypothesis is that severe endothelium loss exposes subendothelial matrix to platelet, leading to its activation and growth factor release. Subsequently, smooth muscle accumulation and proliferation are promoted. 3 When lost endothelial cells (ECs) could not be regenerated properly, neointimal lesions could be formed rapidly. Obviously, reendothelialization of the injured vessel is essential for preventing restenosis. Recent indirect evidence 4, 5 suggests an involve-ment of protein kinase C (PKC) in endothelial proliferation and apoptosis in vitro and in vivo.
PKC is a large family of serine/threonine-specific protein kinases, which are activated by signals such as increases in the concentration of diacylglycerol or Ca 2ϩ . 5 Therefore, PKC enzymes play important roles in several signal transduction cascades. PKC␦ belongs to the PKC family of diacylglycerolactivated serine/threonine kinases and is widely expressed in many cell types, including ECs. 6 PKC␦ contributes to a broad range of cellular responses, such as cell growth, differentiation, and apoptosis. In addition, PKC␦ is involved in the expression of vasohibin-1, 7 an endothelium-derived negative regulator of angiogenesis. 8 Evidence also indicates the effect of PKC␦ on smooth muscle cell (SMC) accumulation in vein grafts 9 and vessel ligation models 10 in mice. However, to our knowledge, the role of PKC␦ in reendothelialization of injured vessels during neointimal formation has not previously been investigated in vivo. Herein, we demonstrate a critical role for PKC␦ in controlling arterial stenosis in response to endothelial injury. We report that, in the absence of PKC␦, mice were highly susceptible to neointimal development coinciding with delayed endothelial wound healing in vivo. This heightened impaired endothelial migration in PKC␦ Ϫ/Ϫ mice. Furthermore, levels of vasohibin-1 in ECs were markedly enhanced in PKC␦ Ϫ/Ϫ animals. Taken together, these results clearly demonstrate that PKC␦ is critical for neointimal formation.
Methods
The PKC␦-deficient (PKC␦ Ϫ/Ϫ ) mice were generated by targeted disruption of the endogenous PKC␦ gene. 9 Genotypic characterization of adult mice with a background of 129/SVxO1a was performed by RT-PCR. Angiopoietin receptor 2 (TIE2)-a gene coding ␤-galactosidase (LacZ) transgenic mice were purchased from The Jackson Laboratory (Bar Harbor, Me). Mice were anesthetized, and the surgical procedure was similar to that described previously. 11 For en face endothelial staining and quantification, the artery was mounted onto a rubber platform with the lumen opened and facing up. Staining was performed as previously described. 12 Detailed information was provided in the supplemental data (available online at http://atvb.ahajournals.org).
Results

Increased Neointimal Lesions in PKC␦ ؊/؊ Mice
To explore whether PKC␦ deficiency could affect neointimal formation in vivo, the femoral artery injury model was established in PKC␦ ϩ/ϩ and PKC␦ Ϫ/Ϫ mice. As shown in Figure 1A , wire injury caused neointimal formation at 3 weeks. The morphological observation showed more severe restenosis lesions in PKC␦ Ϫ/Ϫ mice 3 weeks after injury ( Figure 1A ), whereas less severe restenosis was observed in wild-type mice ( Figure 1A ). Statistical analysis showed that the lesion of the PKC␦ Ϫ/Ϫ mice, when compared with wild-type mice, increased intima thickness by 86% ( Figure  1B) , the intima to media ratio by 53.6% ( Figure 1C ), and vessel wall area by 54% ( Figure 1D ); the luminal area was reduced to 72.6% ( Figure 1E ). These results demonstrated that PKC␦ deficiency was attributed to the development of arteriosclerotic lesions in response to vascular injury.
Cell Composition in Neointima Lesions
Several different cell types contribute to neointima formation in various types of arteriosclerosis. To analyze the cell types in neointima lesions of PKC␦ Ϫ/Ϫ and wild-type mice, immunostaining experiments were performed using several cell markers. As shown in Figure 2A , ␣-smooth muscle actinpositive cells were the major cell component in the lesion, which is similar to data in a previous report. 13 Although the ␣-SMA-positive cells in the media showed no significant difference between PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ mice, there was a 96% increase in neointima lesions of PKC␦ Ϫ/Ϫ mice ( Figure 2B ). For CD4-and macrophage (Mac)-1-positive cells, albeit an increased tendency for positive cells was observed in PKC␦ Ϫ/Ϫ cross sections, no significant differences were statistically detected ( Figure 2C ). This variation was probably because of the limited lymphocytes and macrophages in the lesions. Therefore, these data demonstrate that ␣-SMA-positive cells increase in neointima lesions of PKC␦ Ϫ/Ϫ , compared with wild-type, mice.
SMC Turnover in PKC␦ ؊/؊ Mice
When SMCs were cultivated in vitro, there was no significant difference in cell proliferation between PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ mice (supplemental Figure IA) , which confirms previous data from our laboratory. 14 mice. Proliferating cell nuclear antigen is widely used as a cell-replicating marker and was also used herein for labeling injured vessels from both groups. Summarized data in supplemental Figure IB show a similarity in the percentage of proliferating cell nuclear antigen-positive cells in the neointima of PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ mice at weeks 1 and 2 after injury; this percentage was significantly higher in PKC␦ Ϫ/Ϫ mice at week 3. Double-labeling studies revealed that most proliferating cell nuclear antigen-positive cells were ␣-actin positive (data not shown). Next, we performed the experiments with TUNEL assays to determine cell death in neointimal lesions. Supplemental Figure IC shows quantification of apoptotic/necrotic cells in lesions. TUNEL ϩ cells decreased with time, whereas there was no significant difference between PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ mice. These results indicate that increased neointimal lesions in PKC␦ Ϫ/Ϫ mice may not be induced by alteration of SMCs per se rather than environmental factors.
Delayed Reendothelialization in PKC␦ ؊/؊ Mice
Reendothelialization after vascular injury is closely related to neointima formation. 15 Promotion of reendothelialization inhibited intima hyperplasia, and SMCs proliferated faster in denuded areas than in areas with an endothelial-covered region. 15, 16 It was reasonable to investigate whether there was a difference in reendothelialization between PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ mice in vivo. Data in Figure 3A showed that the remaining ECs migrated to the denuded area to cover and repair the wire-injured area. The newly migrated ECs appeared irregular in their morphological features, which showed a clear border between the original intact area and newly migrated ECs. Staining with EC-specific markers (CD31, endothelial NO synthase, and CD144) was applied to explore the EC migration of PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ mice in vivo ( Figure 3B ). Statistical analysis demonstrated that the migration of PKC␦ Ϫ/Ϫ ECs was slower, which showed only 65% migration rate of PKC␦ ϩ/ϩ ECs ( Figure 3C ).
In addition, there were no statistical differences of proliferation and apoptosis between PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ ECs (supplemental Figure II) . In addition to mature ECs, stem/ progenitor cells could also be attributed to vascular repair. 17, 18 Bone marrow cells were also investigated for the proliferation and differentiation potential in vascular repair (supplemental Figure III ). As shown in supplemental Figure IIIA , there was no difference in colony formation of bone marrow cells between PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ cells. Furthermore, RT-PCR analysis for the endothelial progenitor markers indicated no significant difference in both fresh and cultured bone marrow cells (supplemental Figure IIIB) . To further address the role of bone marrow cells in neointimal formation, we created the chimeric mice by using bone marrow transplantation to irradiated wild-type mice. Data shown in supplemental Figure IV indicate no significant difference in neointimal lesions, intima to media ratio, and lumen size of injured vessels in mice receiving either PKC␦ Ϫ/Ϫ or PKC␦ ϩ/ϩ bone marrow cells. Taken together, these data suggest an important role for mature endothelial migration in neointima formation in PKC␦ Ϫ/Ϫ mice.
Reduced Migration Ability of PKC␦ ؊/؊ ECs in Vitro
To confirm the in vivo results, migration assays were performed in primary cultured ECs in vitro. As shown in Figure  4A , the wound-healing assay revealed reduced migration of PKC␦ Ϫ/Ϫ ECs in culture, which implied a decreased migration baseline in PKC␦ Ϫ/Ϫ cells. Moreover, based on the fact that vascular endothelial growth factor (VEGF) induces EC migration, a Boyden chamber assay was performed in the presence of VEGF. The data showed a dramatic decrease of migrated cells in response to VEGF in PKC␦ Ϫ/Ϫ ECs compared with control cells ( Figure 4B ). Considering that cell migration is a dynamic process involving cytoskeleton reorganization, an EC spreading assay was performed for both types of ECs. As shown in Figure 4C , spreading cells were clarified as 3 types according to size and morphological features (ie, fully spread, semispread, and nonspread cells). The statistical data presented in Figure 4C pharmacological inhibition of PKC␦ with rottlerin was also used to evaluate EC migration. Different concentrations of rottlerin (0.3, 5, and 10 mol/L) were chosen for specific PKC␦ inhibition. As shown in supplemental Figure V , rottlerin inhibited mouse endothelial migration in a dosedependent pattern. Thus, we concluded that PKC␦ deficiency led to decreased EC motility.
Vasohibin-1 Level Is Increased in PKC␦ ؊/؊ ECs
PKC␦ is involved in complex signaling networks in ECs, and its controversial role to diverse stimuli remains elusive. 19 Vasohibin-1, which was recently reported to be crucial for EC migration, has been implicated as a potential link to PKC␦. In the present study, we demonstrated that the vasohibin-1 protein level increased by 83.2% in primary PKC␦ Ϫ/Ϫ ECs compared with wild-type ECs. An even higher level was detected in the PKC␦ stable knockdown EC line ( Figure 5A ).
Immunofluorescent staining of vasohibin-1 confirmed the elevation in primary cultured ECs, and en face staining on aorta also showed a stronger intensity in PKC␦ Ϫ/Ϫ mice ( Figure 5B ). The mRNA level was analyzed by RT-PCR between PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ ECs, indicating no significant difference in the RNA level ( Figure 5C ). To elucidate the mechanism of vasohibin-1 elevation in PKC␦ Ϫ/Ϫ ECs, several inhibitors were tested ( Figure 5D ). Actinomycin D was applied to test whether the protein level difference affected mRNA stability. Cycloheximide was used for translocation after protein synthesis. MG132 could inhibit the degradation of ubiquitin-conjugated proteins. Comparing the vasohibin-1 ratio of ECs treated with PKC␦-shRNA (stable gene silencing) with controls treated with lentivirus vector, it was demonstrated that there were no changes after treatment with either actinomycin D or cycloheximide stimulation ( Figure 5D ). Interestingly, treatment with MG132 increased vasohibin-1 protein expres- sion in both groups to a similar level and ablated the difference of vasohibin-1 between ECs treated with PKC␦-shRNA and virus vectors. These results suggest that the degradation of vasohibin-1 was partially inhibited in PKC␦ gene-silencing cells, which led to high vasohibin-1 accumulation.
Downregulation of Vasohibin-1 Restored PKC␦ ؊/؊ Endothelial Migration
As previously reported, elevated vasohibin-1 protein could inhibit endothelial migration. 20, 21 To confirm the antimigratory role of vasohibin-1 in primary cultured ECs, antisense oligonucleotides of vasohibin-1 and scramble control were transfected into ECs. The reduced expression of vasohibin-1 after small and interfering RNA treatment was confirmed at RNA ( Figure 6A ) and protein ( Figure 6B ) levels in PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ ECs 48 and 72 hours after transfection, respectively. In addition, wound-healing assays were conducted to evaluate endothelial migration after knockdown of vasohibin-1. Figure 6C showed the representative photographs; the lower panel displayed statistical data, suggesting that vasohibin-1 small interfering RNA treatment increased the migration rate in both PKC␦ Ϫ/Ϫ and PKC␦ ϩ/ϩ ECs. More important, in the PKC␦ Ϫ/Ϫ small interfering RNA group, ECs migrated at a similar rate as PKC␦ ϩ/ϩ ECs, indicating that elevated vasohibin-1 expression could restore the suppression of EC migration in PKC␦ Ϫ/Ϫ ECs.
Discussion
The present study demonstrates that PKC␦ deficiency led to increased neointima formation after wire injury, which mimicked clinical restenosis after angioplasty. Moreover, it is elucidated as the first evidence of PKC␦ involvement in delayed endothelial migration in vivo and in vitro. Although SMCs are the major cell component in neointimal lesions, EC migration is responsible for more severe intima hyperplasia in PKC␦ Ϫ/Ϫ mice. The decreased endothelial migration is at least partially mediated by elevated vasohibin-1 retention in PKC␦ Ϫ/Ϫ cells, as verified by restored migration ability of PKC␦ Ϫ/Ϫ ECs after vasohibin-1 knockdown. These findings provide important information for understanding the signal pathways leading to re-endothelialization and neointimal formation.
There is abundant evidence demonstrating the impact of SMC migration and proliferation on neointimal formation in response to endothelial injury. Two factors are crucial: stimuli by growth factors and altered ability of SMCs. 22 Data from the present study (supplemental Figure I) and a previous study 14 indicated that PKC␦ knockout did not change the ability of SMC proliferation. A similar observation was made in artery ligation models by Yamanouchi et al. 10 In addition, decreased SMC apoptosis played an important role in neointimal formation of vein grafts in PKC␦ knockout mice. 9 However, the present data indicate no significant difference in cell apoptosis in wire injury-induced lesions of PKC␦ Ϫ/Ϫ mice (supplemental Figure IC) . The possible explanation for the difference is that the sensed stimulation by SMCs between vein graft and injured artery of these 2 models may differ. In a vein graft, a thin vein wall must bear increased biomechanical forces because of alterations in blood pressure (ie, the vein versus the artery [0 versus 120 mm Hg]), which is a continuous stimulation to vascular cells. A higher level of SMC apoptosis can be seen in neointimal lesions for up to 8 weeks after grafting, whereas increased cell apoptosis in a wire-injured vessel mainly occurs in the first week. This suggests that a different period of SMC apoptosis in these 2 models exerts its different role in neointimal formation.
On the other hand, the timing of reendothelialization after vascular injury could influence platelet activation and subsequent growth factor release. 23 The migration of uninjured ECs precedes proliferation events, and reendothelialization inhibits SMC proliferation and intima hyperplasia. 15 In the present study, we detected slower reendothelialization in PKC␦ Ϫ/Ϫ mice, whereas the timing of SMC proliferation in injured vessels was prolonged. Thus, our findings indicate that impaired endothelial migration may be responsible for delayed reendothelialization, which contributes to more severe restenosis in PKC␦ Ϫ/Ϫ mice.
Recent evidence 24, 25 indicated that stem/progenitor cells are able to repair damaged vessels, especially in the diseased condition (eg, severe loss of ECs after angioplasty). Endogenous endothelial progenitors have multiple origins, including bone marrow, spleen, intestine, liver, adipose tissue, and adventitia. 26 Bone marrow is the most defined source of circulating progenitor cells, which can participate in the process of endothelial repair after injury. Our data provide evidence that there is no major alteration in bone marrow stem cell proliferation and differentiation in PKC␦ Ϫ/Ϫ mice and that bone marrow transplantation did not influence neointimal formation in the model, suggesting that stem/ progenitor cells are not involved in delayed reendothelialization. Alternatively, mature ECs can proliferate and migrate to repair damaged cells. 27 Several treatment strategies for promoting reendothelialization by using angiogenic growth factor (VEGF and fibroblast growth factor 2) and pharmaco-logical agents (angiotensin-converting enzyme inhibitor, statin, estrogen) indirectly demonstrated that mature ECs can participate in endothelial repair in diseased conditions. 15, 28 VEGF induced PKC␦ phosphorylation results in increased EC migration, whereas PKC␦ inhibitor reduced in vitro angiogenesis by VEGF. 29, 30 During this process, PKC␦ was essential for endothelial podosome formation. 31 Therefore, our findings support the notion that PKC␦ deficiency has an implication in VEGF-promoted reendothelialization by showing a dramatic decrease of migrated cells in response to VEGF in PKC␦ Ϫ/Ϫ ECs, compared with the wild type.
Cell migration is a complex process involving receptormediated adhesion and reorganization of the actin cytoskeleton. 32 Moreover, the modulation of proteins by PKC-dependent phosphorylation seems critical. Previously, we provided direct evidence that phosphorylation of cytoskeleton-related proteins is diminished in PKC␦ Ϫ/Ϫ SMCs. 14 Liu et al 33 showed that the association of paxillin with integrins markedly enhanced the rates of integrin-dependent phosphorylation of focal adhesion kinase (FAK) and cell migration. Our findings demonstrated that PKC␦ Ϫ/Ϫ ECs have significantly lower levels of cell spreading ability, suggesting that PKC␦ directly or indirectly influences cytoskeleton rearrangement, which results in altered cell migration.
Vasohibin-1 is a putative angiogenesis inhibitor discovered in 2004 8 ; it is defined as a negative feedback to VEGF stimulation. 34 Vasohibin-1 is expressed in ECs, and it is closely related to angiogenesis during development, cancer, diabetes mellitus, rheumatism, and other physiopathologic conditions. 34 Overexpression of vasohibin-1 inhibited angiogenesis in an animal model. 35 The PKC␦ inhibitor rottlerin inhibited vasohibin-1 expression that was stimulated by VEGF and fibroblast growth factor 2, which led us to consider the role of PKC␦ in vasohibin-1 production. 7 Our results provide evidence that vasohibin-1 protein levels are significantly higher in PKC␦ Ϫ/Ϫ ECs and that knockdown of vasohibin-1 can rescue cell migration of PKC␦ Ϫ/Ϫ ECs. We also demonstrated that the increased level of vasohibin-1 is not through increasing protein synthesis but, rather, inhibiting degradation. How PKC␦ affects vasohibin-1 degradation needs further investigation.
In summary, the present study provides new evidence of the role of PKC␦ on vascular restenosis. Delayed reendothelialization contributed to severe neointima formation in PKC␦ Ϫ/Ϫ mice. The instinctive reaction after PKC␦ knockout resulted in abnormal endothelial migration, which has an implication in altered cytoskeleton rearrangement. PKC␦ also had a role in vasohibin-1 degradation involved in EC migration. Our study indicates that PKC␦ is required for self-repair after vascular injury and highlights a potential target for clinical application for the treatment of restenosis.
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